Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes

Clinical Diabetes

Volumn 36, Issue 2, 2018, Pages 112-119

  Runge, Ava S ^a   Kennedy, Lynn ^a   Brown, Adam S ^a,b   Dove, Abigail E ^b   Levine, Brian J ^b   Koontz, Sophie P ^c   Iyengar, Varun S ^d   Odeh, Sarah A ^b   Close, Kelly L ^a,b   Hirsch, Irl B ^e   Wood, Richard ^c  

^a diaTribe Foundation   (United States)

^b Close Concerns Inc   (United States)

^c dQ A Market Research   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL OUTCOME; DIABETES MELLITUS; DIABETIC PATIENT; DIET; EXERCISE; FALLING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT WORRY; STRESS; TIME;

EID: 85045514695     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/cd17-0094     Document Type: Article

References (31)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046
2. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. Available from CDC.gov. https://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 20 December 2016
3. Lin EH, Rutter CM, Katon W, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 2010;33:264–269
4. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 1987;10:1–19
5. King P, Peacock I, Donnelly R. The U.K. Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999;48:643–648
6. Writing Group for the DCCT/EDIC Research Group; Orchard TJ, Nathan DM, Zinman B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45–53
7. Lung TW, Petrie D, Herman WH, et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care 2014;37:2974–2981
8. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015;313:37–44
9. Singh G, Mithal A, Mannalithara A, et al. Hospitalizations due to severe hypoglyce­mia in patients with type 2 diabetes: a U.S. national perspective (Abstract 279-OR). Diabetes 2013;62(Suppl.1):A72
10. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypo­glycemia in type 2 diabetes. Am J Manag Care 2011;17:673–680
11. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. Plos One 2015;10:e0126427
12. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013;36:3535–3542
13. JDRF Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and inten­sive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476
14. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypogly­caemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254–2263
15. Bergenstal RM, Gal RL, Connor CG, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 2017;167:95–102
16. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473–1478
17. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994–999
18. Gonzalez JS, Safren SA, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007;30:2222–2227
19. Groot MD, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complica­tions: a meta-analysis. Psychosom Med 2001;63:619–630
20. Fisher L, Skaff MM, Mullan JT, Arean P, Glasgow R, Masharani U. A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with type 2 diabetes. Diabetic Med 2008;25:1096–1101
21. Reaney M, Elash CA, Litcher-Kelly L. Patient reported outcomes (PROs) used in recent phase 3 trials for type 2 diabetes: a review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials. Diabetes Res Clin Pract 2016;116:54–67
22. Vieta A, Badia X, Sacristán JA. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. Clin Ther 2011;33:1225–1245
23. Engström MS, Leksell J, Johansson U-B, Gudbjörnsdottir S. What is important for you? A qualitative interview study of living with diabetes and experiences of diabe­tes care to establish a basis for a tailored patient-reported outcome measure for the Swedish National Diabetes Register. BMJ Open 2016;6:e010249
24. Vanstone M, Rewegan A, Brundisini F, Dejean D, Giacomini M. Patient perspec­tives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser 2015;15:1–29
25. Keely E, Traczyk L, Liddy C. Patients’ perspectives on wait times and the refer­ral-consultation process while attending a tertiary diabetes and endocrinology centre: is econsultation an acceptable option? Can J Diabetes 2015;39:325–329
26. Joensen LE, Filges T, Willaing I. Patient perspectives on peer support for adults with type 1 diabetes: a need for diabetes-specific social capital. Patient Prefer Adherence 2016;10:1443–1451
27. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011;13:144–149
28. Sullivan-Bolyai S, Bova C, Johnson K, et al. Engaging teens and parents in collabora­tive practice. Diabetes Educ 2014;40:178–190
29. Nadal JF, Barba EL, Garcia CG, Buil-Cosiales P, Millaruelo JM, Peña MLO. Patient-reported outcomes in type 2 diabetes mellitus: patients’ and pri­mary care physicians’ perspectives in the Spanish health care system. Patient Prefer Adherence 2015;8:1413–1422
30. Goldberg M, Chastang JF, Leclerc A, et al. Socioeconomic, demographic, occupa­tional, and health factors associated with participation in a long-term epidemiologic survey: a prospective study of the French GAZEL cohort and its target population. Am Journal Epidemiol 2001;154:373–384
31. Browne JL, Holmes-Truscott E, Ventura AD, et al. Cohort profiles of the cross-sec­tional and prospective participant groups in the second Diabetes MILES—Australia (MILES-2) study. BMJ Open 2017;7:e012926